drugset
drugset / Trial / NCT04637763

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

NCT04637763 ↗

Phase 1 Unknown 72 enrolled Caribou Biosciences, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.

Timeline

Start
2021-05-26
Primary completion
2025-08
Completion
2025-09

Drugs

EvaluationDrugModalityDoseRoute
Subject CB-010 CRISPR / gene editing — —
Background Cyclophosphamide Other / unclassified — —
Background Fludarabine Small molecule — —

Indications

B-cell non-Hodgkin lymphoma